Medite Cancer Diagnostics, Inc. operates as a medical technology company.
Imperfect balance sheet and overvalued.
- Medite Cancer Diagnostics has significant price volatility in the past 3 months.
- Medite Cancer Diagnostics's last earnings update was 307 days ago.
- Medite Cancer Diagnostics is not covered by any analysts.
Share Price & News
How has Medite Cancer Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
MDIT underperformed the Medical Equipment industry which returned 9.6% over the past year.
MDIT underperformed the Market in United States of America which returned 2.1% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is Medite Cancer Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Medite Cancer Diagnostics undervalued based on future cash flows and its price relative to the stock market?
Price to Book (PB) ratio
Intrinsic Value Based on Future Cash Flows
Unable to calculate intrinsic value for Medite Cancer Diagnostics to establish if it is available at moderate discount.
Unable to calculate intrinsic value for Medite Cancer Diagnostics to establish if it is available at substantial discount.
Price Based on Earnings
Medite Cancer Diagnostics is loss making, we can't compare its value to the US Medical Equipment industry average.
Medite Cancer Diagnostics is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Medite Cancer Diagnostics, we can't assess if its growth is good value.
Price Based on Value of Assets
Medite Cancer Diagnostics is good value based on assets compared to the US Medical Equipment industry average.
How is Medite Cancer Diagnostics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Medite Cancer Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of MDIT’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Medite Cancer Diagnostics's filings and announcements here.
- Explore growth companies in the Healthcare industry.
How has Medite Cancer Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Medite Cancer Diagnostics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Medite Cancer Diagnostics's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Medite Cancer Diagnostics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Medite Cancer Diagnostics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
Return on Assets
It is difficult to establish if Medite Cancer Diagnostics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.
Return on Capital Employed
It is difficult to establish if Medite Cancer Diagnostics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
How is Medite Cancer Diagnostics's financial position?
Financial Position Analysis
Medite Cancer Diagnostics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Medite Cancer Diagnostics's long term commitments exceed its cash and other short term assets.
Debt to Equity History and Analysis
Medite Cancer Diagnostics's level of debt (94%) compared to net worth is high (greater than 40%).
The level of debt compared to net worth has been reduced over the past 5 years (163.1% vs 94% today).
Operating cash flow is negative therefore debt is not well covered.
Unable to confirm if the interest payments on Medite Cancer Diagnostics's debt are well covered by earnings due to lack of past financial data.
High level of physical assets or inventory.
Debt is not covered by short term assets, assets are 0.9x debt.
What is Medite Cancer Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Medite Cancer Diagnostics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Medite Cancer Diagnostics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Medite Cancer Diagnostics has not reported any payouts.
Unable to verify if Medite Cancer Diagnostics's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Medite Cancer Diagnostics has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of Medite Cancer Diagnostics's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
Medite Cancer Diagnostics has no CEO, or we have no data on them.
Board Age and Tenure
The average tenure for the Medite Cancer Diagnostics board of directors is less than 3 years, this suggests a new board.
No 3 month open market individual insider trading information.
Recent Insider Transactions
Susan Weisman (58yo)
- Tenure: 1.7yrs
- Compensation: US$258.99k
Jeff Rencher (52yo)
Chief Marketing & Business Development Officer
- Tenure: 2.3yrs
- Compensation: US$160.10k
John Abeles (75yo)
- Tenure: 20.3yrs
- Compensation: US$123.88k
Joel Kanter (62yo)
- Tenure: 1.8yrs
Gregory Fortunoff (49yo)
- Tenure: 1.7yrs
William Lewis (43yo)
Chairman of Board
- Tenure: 0yrs
- Compensation: US$168.66k
Medite Cancer Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Medite Cancer Diagnostics, Inc.
- Ticker: MDIT
- Exchange: OTCPK
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.946m
- Shares outstanding: 86.18m
- Website: https://medite-group.com
Number of Employees
- Medite Cancer Diagnostics, Inc.
- 10524 Moss Park Road
- Suite 204-357
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MDIT||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Dec 1998|
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, a ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/17 23:55|
|End of Day Share Price||2019/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.